Suppr超能文献

通过热点模拟法合理设计的Musashi蛋白-RNA相互作用抑制剂

Rationally designed inhibitors of the Musashi protein-RNA interaction by hotspot mimicry.

作者信息

Bai Nan, Adeshina Yusuf, Bychkov Igor, Xia Yan, Gowthaman Ragul, Miller Sven A, Gupta Abhishek K, Johnson David K, Lan Lan, Golemis Erica A, Makhov Petr B, Xu Liang, Pillai Manoj M, Boumber Yanis, Karanicolas John

机构信息

Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia PA 19111.

Department of Molecular Biosciences, University of Kansas, Lawrence KS 66045.

出版信息

Res Sq. 2023 Jan 10:rs.3.rs-2395172. doi: 10.21203/rs.3.rs-2395172/v1.

Abstract

RNA-binding proteins (RBPs) are key post-transcriptional regulators of gene expression, and thus underlie many important biological processes. Here, we developed a strategy that entails extracting a "hotspot pharmacophore" from the structure of a protein-RNA complex, to create a template for designing small-molecule inhibitors and for exploring the selectivity of the resulting inhibitors. We demonstrate this approach by designing inhibitors of Musashi proteins MSI1 and MSI2, key regulators of mRNA stability and translation that are upregulated in many cancers. We report this novel series of MSI1/MSI2 inhibitors is specific and active in biochemical, biophysical, and cellular assays. This study extends the paradigm of "hotspots" from protein-protein complexes to protein-RNA complexes, supports the "druggability" of RNA-binding protein surfaces, and represents one of the first rationally-designed inhibitors of non-enzymatic RNA-binding proteins. Owing to its simplicity and generality, we anticipate that this approach may also be used to develop inhibitors of many other RNA-binding proteins; we also consider the prospects of identifying potential off-target interactions by searching for other RBPs that recognize their cognate RNAs using similar interaction geometries. Beyond inhibitors, we also expect that compounds designed using this approach can serve as warheads for new PROTACs that selectively degrade RNA-binding proteins.

摘要

RNA结合蛋白(RBPs)是基因表达的关键转录后调节因子,因此是许多重要生物学过程的基础。在此,我们开发了一种策略,即从蛋白质-RNA复合物的结构中提取“热点药效团”,以创建用于设计小分子抑制剂和探索所得抑制剂选择性的模板。我们通过设计Musashi蛋白MSI1和MSI2的抑制剂来证明这种方法,MSI1和MSI2是mRNA稳定性和翻译的关键调节因子,在许多癌症中上调。我们报告了这一系列新型的MSI1/MSI2抑制剂在生化、生物物理和细胞实验中具有特异性和活性。这项研究将“热点”的范例从蛋白质-蛋白质复合物扩展到蛋白质-RNA复合物,支持RNA结合蛋白表面的“可成药性”,并代表了首批合理设计的非酶RNA结合蛋白抑制剂之一。由于其简单性和通用性,我们预计这种方法也可用于开发许多其他RNA结合蛋白的抑制剂;我们还考虑了通过寻找其他使用相似相互作用几何结构识别其同源RNA的RBPs来识别潜在脱靶相互作用的前景。除了抑制剂,我们还期望使用这种方法设计的化合物可以作为新型PROTACs的弹头,选择性降解RNA结合蛋白。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验